title: [Prevention and treatment of HBV reinfection following liver transplantation].
abstract: OBJECTIVE
  To study the prevention and treatment of HBV reinfection after liver transplantation.
  
  
  METHODS
  Total 19 cases of chronic fulminant hepatitis B, the end-stage of liver cirrhosis and liver carcinoma complicated with HBV cirrhosis. Were performed liver transplantation and given anti-viral drugs pre and post transplantation. Famciclovir was administered in 4 cases, lamivudine in 13 cases and lamivudine+HBIG in 2 cases. The serum HBVM and liver biopsy immunohistochemistry were performed.
  
  
  RESULTS
  Four cases given famciclovir developed reinfection. Serum HBsAg, HBeAg and HBV DNA were positive in 3 cases. Liver biopsy immunohistochemistry showed HBsAg and HBeAg phenotype. Classical viral hepatitis in 1 case occurred, three cases died. In the lamivudin group 7 cases showed positive for HBsAg, 2 cases positive for HBV DNA, 4 cases HBsAg or HBcAg phenotype. One case showed positive for serum anti-HBc the other negative for HBVM, and liver biopsy immunohistochemistry was negative too.
  
  
  CONCLUSIONS
  These date suggest that anti-virus prevention and treatment in pre and post liver transplantation with HBV infected correlative disease is necessary, feasible and effective.
authors.affiliation: Tianjin Infectious Disease Hospital, Tianjin 300192, China.
authors.forename: Guiyu
authors.initials: G
authors.lastname: Yuan
authors.forename: Yili
authors.initials: Y
authors.lastname: Duan
authors.forename: Fengshui
authors.initials: F
authors.lastname: Wang
authors.forename: Shuren
authors.initials: S
authors.lastname: Liang
authors.forename: Limin
authors.initials: L
authors.lastname: Zhu
mesh_terms: D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000328:Adult; D000998:Antiviral Agents; D001706:Biopsy / Q000379:methods; D004279:DNA, Viral / Q000032:analysis; D004338:Drug Combinations; D000077595:Famciclovir; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care / Q000379:methods; D011300:Preoperative Care / Q000379:methods; D012008:Recurrence
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D004338:Drug Combinations; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D007136:Immunoglobulins; D019259:Lamivudine; D015075:2-Aminopurine; D000077595:Famciclovir; C045213:hepatitis B hyperimmune globulin